Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Operating Expenses: 2016-2025

Historic Operating Expenses for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to $51.6 million.

  • UroGen Pharma's Operating Expenses rose 28.03% to $51.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.3 million, marking a year-over-year increase of 32.78%. This contributed to the annual value of $178.3 million for FY2024, which is 28.38% up from last year.
  • As of Q3 2025, UroGen Pharma's Operating Expenses stood at $51.6 million, which was down 16.94% from $62.1 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Operating Expenses ranged from a high of $62.1 million in Q2 2025 and a low of $32.0 million during Q3 2023.
  • Its 3-year average for Operating Expenses is $44.2 million, with a median of $42.8 million in 2024.
  • As far as peak fluctuations go, UroGen Pharma's Operating Expenses dropped by 10.72% in 2021, and later soared by 38.77% in 2024.
  • Over the past 5 years, UroGen Pharma's Operating Expenses (Quarterly) stood at $34.5 million in 2021, then rose by 4.67% to $36.1 million in 2022, then fell by 0.71% to $35.9 million in 2023, then skyrocketed by 38.77% to $49.8 million in 2024, then rose by 28.03% to $51.6 million in 2025.
  • Its Operating Expenses was $51.6 million in Q3 2025, compared to $62.1 million in Q2 2025 and $54.8 million in Q1 2025.